Orange Book product · Brand (NDA)
ERYTHROCIN
ERYTHROMYCIN LACTOBIONATE
At a glance
Approved Prior to Jan 1, 1982
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Active ingredient
ERYTHROMYCIN LACTOBIONATE
Strength
EQ 500MG BASE/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
Not listed
Application
NDA 050182
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a brand (NDA) product. Other products sharing this active ingredient are listed below.
- 1986ERYTHROCINBrand (NDA)
NDA 050609 · HOSPIRA
- 2024ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 216761 · GLAND
- 2022ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 215290 · NEXUS
- 2020ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 211086 · EXELA PHARMA
- 1993ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 063253 · TEVA PARENTERAL
- 1989ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 062993 · BAXTER HLTHCARE
- 1988ERYTHROCINGeneric (ANDA)
ANDA 062586 · ABBOTT
- 1986ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 062604 · ABRAXIS PHARM
- 1986ERYTHROCINGeneric (ANDA)
ANDA 062638 · HOSPIRA
- 1985ERYTHROMYCINGeneric (ANDA)
ANDA 062563 · ELKINS SINN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
